Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer

Cancer Biomarkers

Volumn 10, Issue 2, 2011, Pages 91-99

  McCall, Pamela ^a   Catlow, Jamie ^a   McArdle, Peter A ^b   McMillan, Donald C ^b   Edwards, Joanne ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

C reactive protein; inflammation; p65; prostate cancer

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL TIME;

AGED; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859372801     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0236     Document Type: Article

References (28)

1. www.cancerresearch.uk.org, (2011),
2. P.C. Albertsen, J.A. Hanley, D.F. Gleason and M.J. Barry, Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer, JAMA 11(280) (16 Sept. 1998), 975-980. (Pubitemid 28445095)
3. M. Karin, NF-kappaB as a critical link between inflammation and cancer, Cold Spring Harb Perspect Biol 5(1) (Nov. 2009), a000141.
4. L.M. Coussens and Z.Werb, Inflammation and cancer, Nature 6917(420) (19 Dec. 2002), 860-867. (Pubitemid 36019639)
5. J. Haverkamp, B. Charbonneau and T.L. Ratliff, Prostate inflammation and its potential impact on prostate cancer: a current review, J Cell Biochem 5(103) (1 Apr. 2008), 1344-1353. (Pubitemid 351490705)
6. P.A. McArdle, K. Canna, D.C. McMillan, A.M. McNicol, R. Campbell and M.A. Underwood, The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer, Br J Cancer 3(91) (2 Aug. 2004), 541-543. (Pubitemid 39093576)
7. P.A. McArdle, K. Mir, A.S. Almushatat, A.M. Wallace, M.A. Underwood and D.C. McMillan, Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer, Urol Int 2(77) (2006), 127-129. (Pubitemid 44195771)
8. T.M. Beer, A.S. Lalani, S. Lee, M. Mori, K.M. Eilers, J.G. Curd et al., C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial, Cancer 11(112) (June 2008), 2377-2383.
9. F.R. Greten, L. Eckmann, T.F. Greten, J.M. Park, Z.W. Li, L.J. Egan et al., IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer, Cell 3(118) (6 Aug. 2004), 285-296. (Pubitemid 39061110)
10. E. Pikarsky, R.M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem et al., NF-kappaB functions as a tumour promoter in inflammation-associated cancer, Nature 7007(431) (23 Sept. 2004), 461-466. (Pubitemid 39329586)
11. M.B. Pepys and G.M. Hirschfield, C-reactive protein: a critical update, J Clin Invest 12(111) (June 2003), 1805-1812. (Pubitemid 38057722)
12. B.G.Nordestgaard andK.H.Allin, ElevatedC-reactive protein in the diagnosis, prognosis, and cause of cancer, Crit Rev Clin Lab Sci 48(4) (11 July 11 A.D.), 155-170.
13. T.W. Du Clos and C. Mold, C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity, Immunol Res 3(30) (2004), 261-277. (Pubitemid 39546229)
14. S.K. Venugopal, S. Devaraj and I. Jialal, Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role, Curr Opin Nephrol Hypertens 1(14) (Jan. 2005), 33-37. (Pubitemid 40110697)
15. T. Nozoe, D. Korenaga, M. Futatsugi, H. Saeki, Y. Maehara and K. Sugimachi, Immunohistochemical expression of Creactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker, Cancer Lett 1(192) (20 Mar. 2003), 89-95. (Pubitemid 36287664)
16. W.J. Jabs, M. Busse, S. Kruger, D. Jocham, J. Steinhoff and C. Doehn, Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue, Kidney Int 5(68) (Nov. 2005), 2103-2110. (Pubitemid 43117784)
17. J. Yang, M. Wezeman, X. Zhang, P. Lin, M. Wang, J. Qian et al., Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis, Cancer Cell 3(12) (Sept. 2007), 252-265. (Pubitemid 47333419)
18. S.I. Seo, S.Y. Song, M.R. Kang, M.S. Kim, J.E. Oh, Y.R. Kim et al., Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 andRelA in prostate cancers, APMIS 8(117) (Aug. 2009), 623-628.
19. J.S. Ross, B.V. Kallakury, C.E. Sheehan, H.A. Fisher, R.P. Kaufman, Jr., P. Kaur et al., Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence, Clin Cancer Res 7(10) (1 Apr. 2004), 2466-2472. (Pubitemid 38445708)
20. O. Tatarov, T.J. Mitchell, M. Seywright, H.Y. Leung, V.G. Brunton and J. Edwards, SRC family kinase activity is upregulated in hormone-refractory prostate cancer, Clin Cancer Res 10(15) (15 May 2009), 3540-3549.
21. T. Kirkegaard, J. Edwards, S. Tovey, L.M. McGlynn, S.N. Krishna, R. Mukherjee et al., Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 7(48) (June 2006), 787-794. (Pubitemid 43800937)
22. J. Gerdes, U. Schwab, H. Lemke and H. Stein, Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation, Int J Cancer 1(31) (15 Jan. 1983), 13-20. (Pubitemid 13179545)
23. http://www.swpho.nhs.uk/resource/item.aspx?RID=41287, (2011).
24. S. Akira, IL-6-regulated transcription factors, Int J Biochem Cell Biol 12(29) (Dec. 1997), 1401-1418. (Pubitemid 28153490)
25. F. Kramer, J. Torzewski, J. Kamenz, K. Veit, V. Hombach, J. Dedio et al., Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaBand C/EBPbeta-dependent autocrine interleukin-6 loop, Mol Immunol 9(45) (May 2008), 2678-2689.
26. L.F. Chen and W.C. Greene, Shaping the nuclear action of NF-kappaB, Nat RevMol Cell Biol 5(5) (May 2004), 392-401.
27. S.Y. Huang, C.A. Pettaway, H. Uehara, C.D. Bucana and I.J. Fidler, Blockade of NF-kappa B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, andmetastasis, Oncogene 31(20) (2001), 4188-4197. (Pubitemid 32762193)
28. R. Al Halabi, C.M. Bou, M.R. Abou, H. El Hajj, H. Zahr, R. Schneider-Stock et al., Gallotannin inhibits NFkB signaling and growth of human colon cancer xenografts, Cancer Biol Ther 1(12) (1 July 2011), 59-68.